The Route to New Drug Research and Innovation: The Spatial, Capital and Technological Linkages of Taiwan Bio-Pharma Industry
Date Issued
2012
Date
2012
Author(s)
Chang, Chiao-Ting
Abstract
Taiwan''s bio-pharma industry, on the one hand, appears to cluster established by the Government, on the other hand, emerges a phenomenon of investment to mainland China. Investigating the firms’ resources and local environmental, an analytical framework for research founds. The first and second chapters from the begining of biotech hot or bio-era background, indicating the importance of new drug research and innovation of bio-pharma industry in Taiwan, and analysis of new drug reaserarch and development (R&D) approach and three paradigm shift showing opportunities and limitations of Taiwan''s bio-pharma firms; This study aims to provide the implications of the firms’ practices and innovation in the biopharmaceutical industry, through the action and space-related theory dialogue, including cluster, innovation, action-network, cross-boarder investment discussions. This study recognizes proximity of the “innovation space” and the “institutional environment” as a starting point, and based on firm resources, capital and information analysis for the three dimensions to form the typology of the firms as the actors interact with the environment.
Regarding methodology of research, this study sets up the prospect according to theoretical and industrial analysis, and proves it thorugh data collection and qualitative research with firms by interview as a research method. The case study proves the strategies used by Taiwan''s bio-pharma firms in the drug R&D. The conclusion is presented as follows:
1. Innovative strategy of firms comes from the length of the value chain of new drugs. Firms can cooperate to obtain technology and licensing, and therefore gives rise to many new actors.
2. Taiwan''s SME firms can not afford the capital intensive and long new drug R&D, must be a relay-like segmental value added method.
3. Firms consider the talent, capital and market levels. In biopharmaceutical industry, the production of space and new drug R&D are not directly related.
Finally, this study discuss different innovative biotech pharmaceutical firms and the electronics industry, and a embedded hyperlink point of view to re-review (1) firm practice is reflected in the drug R&D process; (2) new drug R&D must be noted that the beural-firm network link; (3) the new drug R&D value chain must link both the global and local regulations in order to expand the niche and market.
Keywords: new drug research and innovation, bio-pharma industry, venture cvapital, clauste, regulation, value chai
Subjects
new drug research and innovation
bio-pharma industry
venture cvapital
clauste
regulation
value chain
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-101-D90544003-1.pdf
Size
23.54 KB
Format
Adobe PDF
Checksum
(MD5):2dd0c6bb58cb09a1e6171d985e828e11